September 24th 2024
The needle-free option to treat type 1 allergic reactions, including anaphylaxis, was approved for adults and children who weigh 66 lbs or more on August 9, 2024.
September 13th 2024
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
Shaping the Management of COPD with Biologic Therapy
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Palforzia receives expanded label to treat toddlers with peanut allergy
July 30th 2024With the expanded label, Palforzia is now approved to treat individuals aged 1 to 17 years with a confirmed peanut allergy diagnosis, after the treatment was originally approved in 4-to-17-year-olds in January 2020.
Neffy pharmacokinetic profiles compared to epinephrine injections
February 23rd 2024Sarina Tanimoto, MD, MBA, breaks down a poster session regarding the pharmacokinetic profile of neffy, presented at the 2024 American Academy of Allergy, Asthma, & Immunology Annual Meeting in Washington DC from February 23 to February 26, 2024.
Peanut sublingual immunotherapy effectively induces desensitization in younger children
October 17th 2023Desensitization was observed in children aged 1 to 4 years using peanut sublingual immunotherapy (SLIT) compared to placebo, demonstrating a significantly greater median cumulative tolerated dose and higher likelihood of demonstrating remission.
FDA approves pozelimab-bbfg as first CHAPLE disease treatment for children, adults
August 18th 2023Regeneron states all 10 patients achieved normalization of serum albumin and serum IgG concentrations by week 12 in a phase 2/3 trial that investigated the safety and efficacy of pozelimab-bbfg. These concentrations were maintained through 72 weeks.
Oral immunotherapy shown to be effective in desensitization for egg, milk, peanut allergy
July 6th 2023New data on oral immunotherapy to food allergens shows promise for the treatment, though more information with standard interventions and regimens is needed to gain certainty on the efficacy and safety.
Frequent allergies in pediatric atopic dermatitis, eosinophilic esophagitis patients in Puerto Rico
November 16th 2022New data presented at ACAAI 2022 observed various trends in allergies associated with eczema and eosinophilic esophagitis, comparing observed data with that of patients in the United States.